Experts Appearing in Episode III
O. Ross McIntyre, MD was director of Norris Cotton Cancer Center in New Hampshire from 1975-1992. As chair of the Cancer and Leukemia Group B, he assisted in the early development of cancer treatment trials. He is a graduate of Dartmouth College, Dartmouth Medical School, and Harvard Medical School. His work for the last several years has focused on the design, implementation, and analysis of large cancer treatment trials with particular emphasis on leukemia and multiple myeloma. He maintains an interest in cancer epidemiology, screening and prevention, and psychosocial studies in cancer.
Richard Stone, MD is clinical director, Adult Acute Leukemia Program at the Dana-Farber Cancer Institute (DFCI) and associate professor of medicine at Harvard Medical School. He received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women’s Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the clinical director of the Adult Acute Leukemia Program at DFCI and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.
Gary Gilliland, PhD, MD studies the genetics and pathophysiology of human hematologic malignancies, with the goal of translating these findings into improved outcomes for patients. He is professor of medicine at Brigham and Women’s Hospital and Harvard Medical School; a member of the faculty of the department of Genetics in the graduate school of Biomedical and Biological Sciences, also at Harvard Medical School; director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center; and attending physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. He is a residential member of the Harvard Institute of Human Genetics. Dr. Gilliland received his Ph.D. degree in microbiology at the University of California, Los Angeles, under the mentorship of R. John Collier, and his M.D. degree from the University of California, San Francisco. He trained in internal medicine and was chief medical resident at Brigham and Women’s Hospital. His fellowship training in hematology and oncology was done at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute.
Richard J. Barth Jr. MD is associate professor of surgery at Dartmouth Medical School and section chief for general surgery at Dartmouth-Hitchcock Medical Center. Among his clinical interests are surgical oncology and immunotherapy for colon and rectal cancer. Dr. Barth received an A.B. in Biochemical Sciences from Princeton in 1981, and an M.D. from Harvard Medical School in 1985. During the middle of his surgical residency at the New England Deaconess Hospital, he spent 2.5 years in the laboratory of Dr. Steven Rosenberg at the National Cancer Institute. Dr. Barth joined the faculty of Dartmouth Medical School in 1993. Dr. Barth’s lab is investigating the immune response to tumors to develop more effective vaccines.
Randy Noelle, PhD is professor of microbiology and immunology at Dartmouth Medical School and deputy director of the Norris Cotton Cancer Center, as well as co-director of the center’s Immunology and Cancer Immunotherapy Research Program. Dr. Noelle was a post-doctoral fellow at the University of Texas Health Science Center at Dallas from 1980-1984, and in 1984, he joined the faculty of Dartmouth Medical School as an Assistant Professor. In 1995, he was promoted to Professor of Microbiology. Dr. Noelle’s laboratory has identified a novel membrane protein expressed on helper T lymphocytes (Th), CD154. Research is focused on how to block a wide spectrum of immune and autoimmune responses and transplantation rejection.
Daphne Haas-Kogan, MD is assistant professor of Radiation Oncology at the University of California San Francisco and a radiation oncologist at the UCSF Comprehensive Cancer Center. She is an expert in the treatment of pediatric cancers. In addition to caring for patients, she is an accomplished scientist who investigates the effects of radiation therapy on cancer tumors. Her work on this subject has been published widely in medical and science journals. Haas-Kogan, a recipient of numerous awards, completed her medical degree and residency in radiation oncology at the University of California, San Francisco. She is an assistant professor in radiation oncology at UCSF.
Edward A. Sausville, MD, PhD is the associate director of clinical research at the University of Maryland Greenebaum Cancer Center and a faculty member of the University of Maryland School of Medicine. Dr. Sausville was previously associate director of the National Cancer Institute’s Developmental Therapeutics Program, which played a key role in developing many of the new cancer drugs in use today. Dr. Sausville received his M.D. and a Ph.D. in Pharmacology from the Albert Einstein College of Medicine in the Bronx, N.Y., in the late 1970s. He completed his residency at Brigham & Women’s Hospital in Boston in 1982 and a three-year fellowship in the clinical oncology program at the National Cancer Institute in 1985. He then was an attending physician at the U.S. Naval Hospital in Bethesda and Georgetown University Hospital in Washington before returning to the National Cancer Institute in 1990. He has served as associate director of NCI’s Developmental Therapeutics Program since 1994. The Developmental Therapeutics Program is involved in all aspects of drug development from the initial discovery of an agent in a basic research laboratory to wide-scale testing in a national clinical trial. NCI collaborates with government laboratories, research institutes, academic institutions and companies throughout the world in its search for new compounds.